Novel Targeting of Phosphatidylinositol 3-Kinase and Mammalian Target of Rapamycin in Renal Cell Carcinoma

Two phase 2 trials of the novel Akt inhibitor perifosine in patients with advanced renal cell carcinoma after progression on vascular endothelial growth factor-targeted therapy

(2012) Daniel C. Cho et al.   CANCER

The mTOR-Regulated Phosphoproteome Reveals a Mechanism of mTORC1-Mediated Inhibition of Growth Factor Signaling

(2011) P. P. Hsu et al.   SCIENCE

Genetic and Functional Studies Implicate HIF1  as a 14q Kidney Cancer Suppressor Gene

(2011) C. Shen et al.   Cancer Discovery

Phase 3 trial of everolimus for metastatic renal cell carcinoma

(2010) Robert J. Motzer et al.   CANCER

The Efficacy of the Novel Dual PI3-Kinase/mTOR Inhibitor NVP-BEZ235 Compared with Rapamycin in Renal Cell Carcinoma

(2010) D. C. Cho et al.   CLINICAL CANCER RESEARCH

HIF-α Effects on c-Myc Distinguish Two Subtypes of Sporadic VHL-Deficient Clear Cell Renal Carcinoma

(2008) John D. Gordan et al.   CANCER CELL

Targeting the Eukaryotic Translation Initiation Factor 4E for Cancer Therapy

(2008) J. R. Graff et al.   CANCER RESEARCH

Differential Dependence of Hypoxia-inducible Factors 1α and 2α on mTORC1 and mTORC2

(2008) Alfredo Toschi et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

(2008) Robert J Motzer et al.   LANCET

Regulation of TORC1 by Rag GTPases in nutrient response

(2008) Eunjung Kim et al.   NATURE CELL BIOLOGY

Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation

(2008) A. Y. Choo et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA